Quoin Pharmaceuticals Ltd. (QNRX): Total Liabilities

Annual figures by period end, from SEC filings.

$7.27M
As of 2025-12-31
$6.05M
As of 2026-09-30
+1.0%
3-year compound annual growth
-1.9%
5-year compound annual growth
$8.70M2020-12-31: $7.99M2021-12-31: $8.70M2022-12-31: $7.05M2023-12-31: $6.51M2024-12-31: $6.50M2025-12-31: $7.27M$7.27M
2020-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$7.27M+11.8%2026-03-26, Balance as of period end
2024-12-31$6.50M0.0%2026-03-26, Balance as of period end
2023-12-31$6.51M-7.7%2025-03-13, Balance as of period end
2022-12-31$7.05M-18.9%2024-03-14, Balance as of period end
2021-12-31$8.70M+9.0%2023-03-15, Balance as of period end
2020-12-31$7.99Mn/a2022-04-14, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Quoin Pharmaceuticals Ltd. (QNRX)2025-12-31$7.27M+11.8%
Nexentis Technologies Inc. (NXTS)2025-12-31$4.67M+424.1%
Evofem Biosciences, Inc. (EVFM)2025-12-31$89.71M-0.6%
Jyong Biotech Ltd. (MENS)2025-12-31$45.68M+6.5%
Abvc Biopharma, Inc. (ABVC)2025-12-31$7.76M+13.9%
Annovis Bio, Inc. (ANVS)2025-12-31$4.23M-8.4%
Galectin Therapeutics Inc (GALT)2025-12-31$145.73M+20.9%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$85.04M+6.2%
Phio Pharmaceuticals Corp. (PHIO)2025-12-31$1.34M+32.0%

Compare QNRX, NXTS, EVFM, MENS side by side · Screen every company in Pharmaceutical Preparations ↗